MBQ Pharma

Booth 2335
San Juan, Puerto Rico, United States
MBQ Pharma is a clinical-stage pharmaceutical company developing highly effective anti-cancer agents to improve overall survival. Our lead compound MBQ-167 is a small molecule that markedly inhibits tumor growth and metastasis. Our compounds selectively target the GTPases Rac and Cdc42, which are central drivers of cancer cell survival, proliferation, and invasion leading to tumor growth and metastasis. MBQ-167 abolishes cancer cell motility, growth, and survival, essential elements of cancerous growth. Strong published and unpublished data show that MBQ-167 targets metastasis by blocking cancer cells from leaving the primary tumor, impeding the establishment of new metastases, and reducing existing metastases. Compared to other approaches targeting Rac and Cdc42, MBQ-167 has an unparalleled degree of specificity, affinity, and safety, and most importantly, its efficacy is not affected by mutations of the targeted molecules.

Our first indication for our lead compound MBQ-167 is the treatment of patients with advanced breast cancer, including those with metastasis. Emphasis will be on treating diseases with high unmet medical needs, such as triple-negative breast cancer (TNBC) and metastatic cancer. Later programs will include studies on disease recurrence prevention, for example, for those patients with existing bone marrow micrometastases and/or circulating tumor cells. MBQ-167 holds great promise for treating CNS tumors because its chemical properties indicate the ability to cross the blood-brain barrier. Moreover, MBQ-167 has a strong potential to be effective in treating other solid tumors since Rac and Cdc42 are central to metastatic progression in multiple cancer types.

In June 2022, FDA granted MBQ Pharma an IND for its First Human Trial in patients with advanced breast cancer.